Finding hope with a rare disease

Planning for a future beyond neuromyelitis optica spectrum disorder (NMOSD)

Through medical innovation and partnerships, Roche is providing new options to people living with NMOSD, a rare autoimmune disorder, to help them retain as much independence as possible.

NMOSD is a rare, lifelong and debilitating autoimmune disease of the central nervous system, primarily damaging the optic nerve(s) and spinal cord. It affects around 200,000 people worldwide and is most common among women, affecting people in the prime of their lives, usually in their 30s and 40s.

People with NMOSD experience unpredictable, severe relapses directly causing cumulative, irreversible, neurological damage and disability. One relapse may lead to permanent blindness, muscle weakness, paralysis and, in some cases, death. Before targeted diagnostic and treatment of NMOSD, within five years 50% of individuals with NMOSD required a wheelchair and 62% of people with NMOSD were functionally blind.

As a result, preventing relapses is the primary goal for NMOSD management.

Tags: Patients, Neuroscience